Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Cvitkovic

Showing results (121-130 of 129) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 129 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patientsJ Alexandre, P Bleuzen, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use programS Brienza, M A Bensmaïne, P Soulié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracilP Wibault, M A Bensmaine, M de Forni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsC Louvet, T André, J M Tigaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patientsM Ducreux, E Mitry, M Ould-Kaci, et al.
Anti-Cancer Drugs|October 18, 2001
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in manR W Sparidans, H Rosing, M J Hillebrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study GroupD Schrijvers, J Johnson, U Jiminez, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusionC van Kesteren, R A Mathĵt, L López-Lázaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding studyC van Kesteren, E Cvitkovic, A Taamma, et al.
Pageof 13

Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2000
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patientsJ Alexandre, P Bleuzen, J Bonneterre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use programS Brienza, M A Bensmaïne, P Soulié, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracilP Wibault, M A Bensmaine, M de Forni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsC Louvet, T André, J M Tigaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patientsM Ducreux, E Mitry, M Ould-Kaci, et al.
Anti-Cancer Drugs|October 18, 2001
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in manR W Sparidans, H Rosing, M J Hillebrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study GroupD Schrijvers, J Johnson, U Jiminez, et al.
Cancer Chemotherapy and Pharmacology|January 22, 2002
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusionC van Kesteren, R A Mathĵt, L López-Lázaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2001
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding studyC van Kesteren, E Cvitkovic, A Taamma, et al.
Pageof 13